Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination

Blood Adv. 2023 Jan 10;7(1):174-177. doi: 10.1182/bloodadvances.2022008989.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • BNT162 Vaccine*
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2

Substances

  • BNT162 Vaccine
  • COVID-19 Vaccines